ARTICLE | Clinical News

Anthim obiltoxaximab: Phase III data

October 13, 2014 7:00 AM UTC

An open-label, U.S. Phase III trial in 40 healthy adult volunteers showed that the addition of ciprofloxacin to a single dose of 16 mg/kg IV obiltoxaximab led to no increase in the frequency of adverse events reported vs. obiltoxaximab alone. Additionally, ciprofloxacin had no effect on the pharmacokinetics of obiltoxaximab. The most common adverse event related to obiltoxaximab reported was urticaria and no serious adverse events related to obiltoxaximab were reported. Elusys plans to submit a BLA to FDA for obiltoxaximab in 1Q15. ...